rev:  August 19, 2004

HOME (index page)

Return  (alphabetical antibody page)


  ANTIBODIES  

(anti-Human and others as indicated)

RDI Divison of researchd Industries Intl  offers a wide line of  antibodies. Since no one antibody works best for all applications (neutralization, blotting, ELISA, etc), we offer many different types of antibodies to help solve this problem. Please inquire for other applications or types of antibodies not listed below.


Uroplakin II clone AU1 (available as 50ug purified or 5ml Ready To Use TCS format)
Mab to Uroplakin III (human/bovine)

Cat#RDI-PRO651108     $345.00/vial  5ml TCS formulation

cat#RDI-PRO610108    $410.00/1vial  $375/vial 10+   50ug (lyophilized) with 0.5%BSA & 0.09% NaN3

Clone                                 AU1

Category                            Mouse monoclonal

Immunoglobulin Class        IgG1

Form/Purification               Hybridoma culture supernatant

Antigen

                                           Asymetric unit membrane (AUM) preparation from bovine urinary bladder

Description/Specificity     Mab AU1 reacts specifically with uroplakin III present in the superficial cell layer of the urothelium. Together with uroplakins UP 1A, UP 1b, and UP II, uroplakin III contributes in constituting the asymetrical unti membrane of the plaques of urothelial glycoprotein (47kD) and has been shown to be a specific marker of terminal urothelial differentiation (Wu et al., 1983, 1994).

                                      Antibody AU1 strongly stains the urothelial surface membrane in paraffin sections of human renal pelvis, ureter, bladder, and uretha. About 60% of human transitional cell carcinomas (including metastases) maintain focal (sometimes very limited) expression of uroplakin III. Until know, no uroplakin staining was found in any non-urothelial carcinoma (Moll et al 1995). Uroplakin III may thus serve as a specific urothelial differentiaition marker in cases of metastatic carcinomas with unclear primary tumor

Antigen Recognized in Species (tested so far)     Human, bovine, rat (canine reported)

Application Suitable for

                                          · immunohistochemistry on paraffin-embedded tissue (NOT ON FROZEN SECTIONS)

                                          · immunoblotting (Western)

Working Dilution                Ready-to-use for immunohistochemistry (cat#RDI-PRO651108)

                                            1:10 for histochemistry  (cat#RDI-PRO610108)

Incubation Time                   1 h at RT for immunohistochemistry

Storage                                 At 2-8°C

Quantity                                5 ml (contains 0.09% NaN3) cat#RDI-PRO651108

                                             50ug in 1ml PBS with 0.5%BSA & 0.1% NaN3  cat#RDI-PRO610108

References



1. Wu XR, Sun TT:Molecular cloning of a 47kD tissue specific and differentiation-dependent urothelial cell surface glycoprotein. J. Cell Sci. 106, 31-43 (1993)

2. Wu XR, Lin JH, Waltz T, Haner M, Yu J, Aebi U, Sun TT:Mammalian uroplakins:a group of highly conserved urothelial differentiation- releated membrane proteins. J. Biol Chem 269:13716-13724 (1994)

3. Moll R, Wu XR, Lin JH, Sun TT: Uroplakins, specific membrane proteins of urothelial umbrella cells, as histological markers of metastatic transitional cell carcinomas. Am J Pathol. 147, 1383-1397 (1995)

4. Kaufmann O, Volmerig J, Dietel M. Uroplakin III is a highly specific and moderately sensitive immunohistochemisal marker for primary and metastatic urothelial carcinomas.  Am J, Clin Pathol 2000;113:683-687

ABSTRACT:-Uroplakins are specific differentiation products of terminally differentiated superficial urothelial cells, The authors tested the value of a new commerically available monoclonal antibody agaianst uroplakin III (clone AU1) as a paraffin-reactive immunohistochemical marker for primary and metastatic urothelial carcinomas. The study cases included 67 urothelial carcinomas of the urinary tract (35 primary tumors, 32 metastases) and 318 nonurothelial carcinomas, as well as five benign Brenner tumors and two transitional cell carcinomas of the ovaries. Uroplakin III was detected in 21 (60 precent) of the primary urothelial carcinomas and 17 (53 percent) of the metastases, resulting in an overall sensitivity of 0.57. The studied Brenner tumors also were immunoreactive for uorplakin III. All other studied carcinomas were consistently uroplakin III negative( specificity, 1.0). Researchers found the new monoclonal anitbody clone AU1 against uroplakin III to be highly specific paraffin-reactive immunohistochemical markeer for urothelial tumors with a moderate sensitiivty for identifying primary and metastatic urothelial carcinomas.

5. Hu P et al, Ablation of Uroplakin III gene results in small urothelial plaques, urothelial leakag, and vesicoureteral reflux, J. Cell Biol 151, 961-971(2000)

6. Riedel I et al, Brenner Tumors but not transitional cell carcinomas of the ovary show urothelial differentiation:Immunohistochemical staining of urothelial markers, including cytokeratins and uroplakins. Virchows Arch 438,181-191 (2001)

7. Liang F-X et al, Organziation of uroplakin subunits:transmembrane topology, pair formation and plaque composition. Biochem J. 355, 13-18 (2001)

8. Romih R et al: Uroplakins and cytokeratins in the regenerating rat urothelium after sodium saccharin treatment Histochem Cell Biol 109:263-269 (1998)

For In Vitro Research Use Only


RDI Divison of researchd Industries Intl

San Jose, 95123 CA Snell ave 658

USA

or (800) 370-2222

EMAIL:margaret@cellular-research.com

Return  (alphabetical antibody list)

Ordering terms